Compound ID | 2101
Synonym(s): Ro 19-5247 | T2525 | tomiron | Cefteram | T-2588 | cefteram pivoxil (prodrug) | cefetamet
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor. Binds to penicillin-binding proteins (PBP); inactivated by extended-spectum beta-lactamases (ESBL) |
| Target Pathogen: | This compound demonstrated no activity against staphylococci but ten times more active than cefaclor and cefalexin against Streptococcus pyogenes; active against Gram-positive bacteria and against many Enterobacteriaceae |
| Description: | Faoagali JL. The antibiotic susceptibilities of 1659 clinical isolates to RO 15-8074, RO 19-5247 and RO 23-6240. Aust-J-Hosp-Pharm 1989;19214-217; semisynthetic Cephalosporine (cephem), derived from Cephalosporin C. Oral application as prodrug (Cefteram pivoxil); a third generation cephalosporin |
| Institute where first reported: | Toyama Chemical, Japan; Roche, Japan |
| Year first mentioned: | 1984 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| Reason dropped: | In preclinical trials on mice, penetration through the blood brain barrier and placenta were low (2) |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/6537431 |
| Guide to Pharmacology: | cefteram |
| Citations: |
|